Liver Dysfunction, Visceral Fat
Conditions
Keywords
High visceral fat, Liver enzymes, Aminotransferase, Mild calorie restriction
Brief summary
To investigate weight loss effect with mild calorie restriction on circulating levels of liver enzymes in nondiabetic and overweight subjects with high visceral fat area \[visceral fat area (VFA) at L4 ≥ 100 cm²\].
Detailed description
A 12-week randomized, placebo-controlled study was conducted on 80 nondiabetic and overweight subjects with high VFA. The participants divided into two groups: 12-week mild calorie restriction (a 300 kcal/day intake reduction, n=40) or no treatment (control, n=40). The randomization was according to computer-generated block randomization (placebo:test = 1:1). Before and after intervention period, venous blood samples were obtained from the subjects, and biochemical parameters including circulating liver enzymes were measured.
Interventions
BEHAVIORALControl group
The participants who included in control group did not receive any treatment.
BEHAVIORALWeight loss group
The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
Sponsors
Yonsei University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Able to give informed consent * 20-60 years old * Males and females * Overweight (25.0 kg/m²≤ BMI \<30 kg/m²) * Absence of pregnancy or breast-feeding * Stable body weight (body weight change \<1kg for 3 months before screening) * High visceral fat (VFA) at L4 (VFA at L4 ≥100 cm²) * Without hypertension, type 2 diabetes, cardiovascular disease, or thyroid disease * No use medication affecting body weight, energy expenditure, or glucose control for the last 6 months
Exclusion criteria
* Prior history of Cushing syndrome or malignancy * Prior history of liver disease including chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, or drug-induced liver disease * Excess alcohol intake (based on WHO standard) * History of intentional reduction in weight in the preceding 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visceral fat area at L4 (CT) | At baseline |
| Change from baseline visceral fat area at L4 at 12-week (CT) | At baseline and 12-week follow-up |
| Serum fatty acid levels (Relative peak area) | At baseline |
Secondary
| Measure | Time frame |
|---|---|
| Fat percentage (DEXA) | At baseline |
| Change from baseline fat mass at 12-week (DEXA) | At baseline and 12-week follow-up |
| Change from baseline fat percentage at 12-week (DEXA) | At baseline and 12-week follow-up |
| Fat mass (DEXA) | At baseline |
Countries
South Korea
Outcome results
None listed